Bristol-Myers Squibb's flurry of dealmaking has continued with en expansion of its partnership with BridgeBio on drugs targeting SHP2, in the hope of combining them with its cancer immunotherapy ...
Bristol Myers Squibb has moved to take full control of the CAR-T therapy it partners with 2seventy bio, agreeing to buy the biotech for around $286 million. The $5.00-per-share offer – announced at ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results